ID   CP2AD_HUMAN             Reviewed;         494 AA.
AC   Q16696; Q53YR8; Q6R569; Q6R570; Q9H2X2;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   11-OCT-2005, sequence version 3.
DT   10-MAY-2017, entry version 163.
DE   RecName: Full=Cytochrome P450 2A13;
DE            EC=1.14.14.1;
DE   AltName: Full=CYPIIA13;
GN   Name=CYP2A13;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7668294;
RA   Fernandez-Salguero P., Hoffman S.M., Cholerton S., Mohrenweiser H.,
RA   Raunio H., Rautio A., Pelkonen O., Huang J.D., Evans W.E., Idle J.R.;
RT   "A genetic polymorphism in coumarin 7-hydroxylation: sequence of the
RT   human CYP2A genes and identification of variant CYP2A6 alleles.";
RL   Am. J. Hum. Genet. 57:651-660(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], CHARACTERIZATION, AND TISSUE SPECIFICITY.
RX   PubMed=11016631;
RA   Su T., Bao Z., Zhang Q.Y., Smith T.J., Hong J.Y., Ding X.;
RT   "Human cytochrome P450 CYP2A13: predominant expression in the
RT   respiratory tract and its high efficiency metabolic activation of a
RT   tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-
RT   butanone.";
RL   Cancer Res. 60:5074-5079(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS GLU-158 AND LEU-323.
RX   PubMed=15063809; DOI=10.1016/j.bbrc.2004.03.092;
RA   Cauffiez C., Lo-Guidice J.-M., Quaranta S., Allorge D., Chevalier D.,
RA   Cenee S., Hamdan R., Lhermitte M., Lafitte J.-J., Libersa C.,
RA   Colombel J.-F., Stuecker I., Broly F.;
RT   "Genetic polymorphism of the human cytochrome CYP2A13 in a French
RT   population: implication in lung cancer susceptibility.";
RL   Biochem. Biophys. Res. Commun. 317:662-669(2004).
RN   [4]
RP   FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF LEU-110;
RP   ALA-117; SER-208; ALA-213; PHE-300; ALA-301; MET-365; LEU-366; GLY-369
RP   AND HIS-372.
RX   PubMed=18779312; DOI=10.1124/dmd.108.023770;
RA   DeVore N.M., Smith B.D., Urban M.J., Scott E.E.;
RT   "Key residues controlling phenacetin metabolism by human cytochrome
RT   P450 2A enzymes.";
RL   Drug Metab. Dispos. 36:2582-2590(2008).
RN   [5]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 29-494 IN COMPLEX WITH HEME.
RX   PubMed=17540336; DOI=10.1016/j.abb.2007.04.028;
RA   Sansen S., Hsu M.H., Stout C.D., Johnson E.F.;
RT   "Structural insight into the altered substrate specificity of human
RT   cytochrome P450 2A6 mutants.";
RL   Arch. Biochem. Biophys. 464:197-206(2007).
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 31-494 IN COMPLEX WITH
RP   SUBSTRATE ANALOG AND HEME.
RX   PubMed=17428784; DOI=10.1074/jbc.M702361200;
RA   Smith B.D., Sanders J.L., Porubsky P.R., Lushington G.H., Stout C.D.,
RA   Scott E.E.;
RT   "Structure of the human lung cytochrome P450 2A13.";
RL   J. Biol. Chem. 282:17306-17313(2007).
RN   [7]
RP   VARIANT CYS-257.
RX   PubMed=12130698; DOI=10.1124/jpet.302.2.416;
RA   Zhang X., Su T., Zhang Q.Y., Gu J., Caggana M., Li H., Ding X.;
RT   "Genetic polymorphisms of the human CYP2A13 gene: identification of
RT   single-nucleotide polymorphisms and functional characterization of an
RT   Arg257Cys variant.";
RL   J. Pharmacol. Exp. Ther. 302:416-423(2002).
RN   [8]
RP   VARIANTS GLN-25; GLN-101; THR-134 INS; GLU-158; TYR-453 AND CYS-494.
RX   PubMed=15618722; DOI=10.2133/dmpk.18.86;
RA   Fujieda M., Yamazaki H., Kiyotani K., Muroi A., Kunitoh H.,
RA   Dosaka-Akita H., Sawamura Y., Kamataki T.;
RT   "Eighteen novel polymorphisms of the CYP2A13 gene in Japanese.";
RL   Drug Metab. Pharmacokinet. 18:86-90(2003).
RN   [9]
RP   VARIANTS GLN-25 AND CYS-257.
RX   PubMed=12721789; DOI=10.1007/s10038-003-0021-7;
RA   Saito S., Iida A., Sekine A., Kawauchi S., Higuchi S., Ogawa C.,
RA   Nakamura Y.;
RT   "Catalog of 680 variations among eight cytochrome p450 (CYP) genes,
RT   nine esterase genes, and two other genes in the Japanese population.";
RL   J. Hum. Genet. 48:249-270(2003).
CC   -!- FUNCTION: Exhibits a coumarin 7-hydroxylase activity. Active in
CC       the metabolic activation of hexamethylphosphoramide, N,N-
CC       dimethylaniline, 2'-methoxyacetophenone, N-
CC       nitrosomethylphenylamine, and the tobacco-specific carcinogen, 4-
CC       (methylnitrosamino)-1-(3-pyridyl)-1-butanone. Possesses phenacetin
CC       O-deethylation activity. {ECO:0000269|PubMed:18779312}.
CC   -!- CATALYTIC ACTIVITY: RH + [reduced NADPH--hemoprotein reductase] +
CC       O(2) = ROH + [oxidized NADPH--hemoprotein reductase] + H(2)O.
CC   -!- COFACTOR:
CC       Name=heme; Xref=ChEBI:CHEBI:30413;
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=10.7 uM for phenacetin {ECO:0000269|PubMed:18779312};
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Peripheral
CC       membrane protein. Microsome membrane; Peripheral membrane protein.
CC   -!- TISSUE SPECIFICITY: Expressed in liver and a number of
CC       extrahepatic tissues, including nasal mucosa, lung, trachea,
CC       brain, mammary gland, prostate, testis, and uterus, but not in
CC       heart, kidney, bone marrow, colon, small intestine, spleen,
CC       stomach, thymus, or skeletal muscle.
CC       {ECO:0000269|PubMed:11016631}.
CC   -!- POLYMORPHISM: The frequencies of the Cys-257 allele in white,
CC       black, Hispanic, and Asian individuals are 1.9%, 14.4%, 5.8%, and
CC       7.7%, respectively. The Cys-257 variant is 37 to 56% less active
CC       than the wild-type Arg-257 protein toward all substrates tested.
CC   -!- SIMILARITY: Belongs to the cytochrome P450 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Cytochrome P450 Allele Nomenclature Committee;
CC       Note=CYP2A13 alleles;
CC       URL="http://www.cypalleles.ki.se/cyp2a13.htm";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U22028; AAB40519.1; -; Genomic_DNA.
DR   EMBL; AF209774; AAG35775.1; -; mRNA.
DR   EMBL; AY513604; AAR90935.1; -; mRNA.
DR   EMBL; AY513605; AAR90936.1; -; mRNA.
DR   EMBL; AY513606; AAR90937.1; -; mRNA.
DR   EMBL; AY513608; AAR90939.1; -; mRNA.
DR   EMBL; AY513609; AAR90940.1; -; mRNA.
DR   CCDS; CCDS12571.1; -.
DR   PIR; I38966; I38966.
DR   RefSeq; NP_000757.2; NM_000766.4.
DR   UniGene; Hs.567252; -.
DR   PDB; 2P85; X-ray; 2.35 A; A/B/C/D/E/F=26-494.
DR   PDB; 2PG5; X-ray; 1.95 A; A/B/C/D=31-494.
DR   PDB; 2PG6; X-ray; 2.53 A; A/B/C/D=31-494.
DR   PDB; 2PG7; X-ray; 2.80 A; A/B/C/D=31-494.
DR   PDB; 3T3S; X-ray; 3.00 A; A/B/C/D/E/F/G/H=31-494.
DR   PDB; 4EJG; X-ray; 2.50 A; A/B/C/D/E/F/G/H=31-494.
DR   PDB; 4EJH; X-ray; 2.35 A; A/B/C/D/E/F/G/H=31-494.
DR   PDB; 4EJI; X-ray; 2.10 A; A=31-494.
DR   PDBsum; 2P85; -.
DR   PDBsum; 2PG5; -.
DR   PDBsum; 2PG6; -.
DR   PDBsum; 2PG7; -.
DR   PDBsum; 3T3S; -.
DR   PDBsum; 4EJG; -.
DR   PDBsum; 4EJH; -.
DR   PDBsum; 4EJI; -.
DR   ProteinModelPortal; Q16696; -.
DR   SMR; Q16696; -.
DR   BioGrid; 107931; 1.
DR   STRING; 9606.ENSP00000332679; -.
DR   BindingDB; Q16696; -.
DR   ChEMBL; CHEMBL3542436; -.
DR   DrugBank; DB00553; Methoxsalen.
DR   DrugBank; DB00184; Nicotine.
DR   DrugBank; DB03783; Phenacetin.
DR   DrugBank; DB00624; Testosterone.
DR   iPTMnet; Q16696; -.
DR   PhosphoSitePlus; Q16696; -.
DR   BioMuta; CYP2A13; -.
DR   DMDM; 77416854; -.
DR   EPD; Q16696; -.
DR   PaxDb; Q16696; -.
DR   PeptideAtlas; Q16696; -.
DR   PRIDE; Q16696; -.
DR   DNASU; 1553; -.
DR   Ensembl; ENST00000330436; ENSP00000332679; ENSG00000197838.
DR   GeneID; 1553; -.
DR   KEGG; hsa:1553; -.
DR   UCSC; uc002opt.5; human.
DR   CTD; 1553; -.
DR   DisGeNET; 1553; -.
DR   GeneCards; CYP2A13; -.
DR   HGNC; HGNC:2608; CYP2A13.
DR   HPA; HPA046713; -.
DR   HPA; HPA047262; -.
DR   MalaCards; CYP2A13; -.
DR   MIM; 608055; gene.
DR   neXtProt; NX_Q16696; -.
DR   OpenTargets; ENSG00000197838; -.
DR   PharmGKB; PA27101; -.
DR   eggNOG; KOG0156; Eukaryota.
DR   eggNOG; COG2124; LUCA.
DR   GeneTree; ENSGT00760000118775; -.
DR   HOGENOM; HOG000036992; -.
DR   HOVERGEN; HBG015789; -.
DR   InParanoid; Q16696; -.
DR   KO; K17685; -.
DR   OMA; QFTSTSM; -.
DR   OrthoDB; EOG091G0BT8; -.
DR   PhylomeDB; Q16696; -.
DR   TreeFam; TF352043; -.
DR   Reactome; R-HSA-211935; Fatty acids.
DR   Reactome; R-HSA-211981; Xenobiotics.
DR   Reactome; R-HSA-211999; CYP2E1 reactions.
DR   Reactome; R-HSA-5423646; Aflatoxin activation and detoxification.
DR   SABIO-RK; Q16696; -.
DR   EvolutionaryTrace; Q16696; -.
DR   GeneWiki; CYP2A13; -.
DR   GenomeRNAi; 1553; -.
DR   PRO; PR:Q16696; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000197838; -.
DR   CleanEx; HS_CYP2A13; -.
DR   Genevisible; Q16696; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0031090; C:organelle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0008392; F:arachidonic acid epoxygenase activity; IBA:GO_Central.
DR   GO; GO:0070330; F:aromatase activity; IEA:UniProtKB-EC.
DR   GO; GO:0008389; F:coumarin 7-hydroxylase activity; TAS:Reactome.
DR   GO; GO:0020037; F:heme binding; IDA:UniProtKB.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0019825; F:oxygen binding; TAS:Reactome.
DR   GO; GO:0009804; P:coumarin metabolic process; TAS:Reactome.
DR   GO; GO:0019373; P:epoxygenase P450 pathway; IBA:GO_Central.
DR   GO; GO:0006805; P:xenobiotic metabolic process; TAS:Reactome.
DR   InterPro; IPR001128; Cyt_P450.
DR   InterPro; IPR017972; Cyt_P450_CS.
DR   InterPro; IPR002401; Cyt_P450_E_grp-I.
DR   InterPro; IPR008067; Cyt_P450_E_grp-I_CYP2A-like.
DR   Pfam; PF00067; p450; 1.
DR   PRINTS; PR00463; EP450I.
DR   PRINTS; PR01684; EP450ICYP2A.
DR   PRINTS; PR00385; P450.
DR   SUPFAM; SSF48264; SSF48264; 1.
DR   PROSITE; PS00086; CYTOCHROME_P450; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Endoplasmic reticulum; Heme; Iron;
KW   Membrane; Metal-binding; Microsome; Monooxygenase; Oxidoreductase;
KW   Polymorphism; Reference proteome.
FT   CHAIN         1    494       Cytochrome P450 2A13.
FT                                /FTId=PRO_0000051676.
FT   METAL       439    439       Iron (heme axial ligand).
FT   BINDING     297    297       Substrate.
FT   VARIANT      25     25       R -> Q (in allele CYP2A13*2;
FT                                dbSNP:rs8192784).
FT                                {ECO:0000269|PubMed:12721789,
FT                                ECO:0000269|PubMed:15618722}.
FT                                /FTId=VAR_018334.
FT   VARIANT     101    101       R -> Q (in allele CYP2A13*4;
FT                                dbSNP:rs148044792).
FT                                {ECO:0000269|PubMed:15618722}.
FT                                /FTId=VAR_018335.
FT   VARIANT     134    134       T -> TT (in allele CYP2A13*3).
FT                                {ECO:0000269|PubMed:15618722}.
FT                                /FTId=VAR_018336.
FT   VARIANT     158    158       D -> E (in allele CYP2A13*3 and allele
FT                                CYP2A13*8; dbSNP:rs112337232).
FT                                {ECO:0000269|PubMed:15063809,
FT                                ECO:0000269|PubMed:15618722}.
FT                                /FTId=VAR_018337.
FT   VARIANT     257    257       R -> C (in allele CYP2A13*2;
FT                                dbSNP:rs8192789).
FT                                {ECO:0000269|PubMed:12130698,
FT                                ECO:0000269|PubMed:12721789}.
FT                                /FTId=VAR_013835.
FT   VARIANT     323    323       V -> L (in allele CYP2A13*9).
FT                                {ECO:0000269|PubMed:15063809}.
FT                                /FTId=VAR_018356.
FT   VARIANT     453    453       F -> Y (in allele CYP2A13*5;
FT                                dbSNP:rs72547590).
FT                                {ECO:0000269|PubMed:15618722}.
FT                                /FTId=VAR_018338.
FT   VARIANT     494    494       R -> C (in allele CYP2A13*6;
FT                                dbSNP:rs138870349).
FT                                {ECO:0000269|PubMed:15618722}.
FT                                /FTId=VAR_018339.
FT   MUTAGEN     110    110       L->V: Decreases phenacetin O-deethylation
FT                                activity 8 fold.
FT                                {ECO:0000269|PubMed:18779312}.
FT   MUTAGEN     117    117       A->V: Increases phenacetin O-deethylation
FT                                activity 5 fold.
FT                                {ECO:0000269|PubMed:18779312}.
FT   MUTAGEN     208    208       S->I: Decreases phenacetin O-deethylation
FT                                activity 10 fold.
FT                                {ECO:0000269|PubMed:18779312}.
FT   MUTAGEN     213    213       A->S: Decreases phenacetin O-deethylation
FT                                activity 2 fold.
FT                                {ECO:0000269|PubMed:18779312}.
FT   MUTAGEN     300    300       F->I: Decreases phenacetin O-deethylation
FT                                activity 40 fold.
FT                                {ECO:0000269|PubMed:18779312}.
FT   MUTAGEN     301    301       A->G: Decreases phenacetin O-deethylation
FT                                activity 20 fold.
FT                                {ECO:0000269|PubMed:18779312}.
FT   MUTAGEN     365    365       M->V: Decreases phenacetin O-deethylation
FT                                activity 7 fold.
FT                                {ECO:0000269|PubMed:18779312}.
FT   MUTAGEN     366    366       L->I: Increases phenacetin O-deethylation
FT                                activity 3 fold.
FT                                {ECO:0000269|PubMed:18779312}.
FT   MUTAGEN     369    369       G->S: Decreases phenacetin O-deethylation
FT                                activity 9 fold.
FT                                {ECO:0000269|PubMed:18779312}.
FT   MUTAGEN     372    372       H->R: Decreases phenacetin O-deethylation
FT                                activity 3 fold.
FT                                {ECO:0000269|PubMed:18779312}.
FT   CONFLICT    208    208       S -> R (in Ref. 1; AAB40519).
FT                                {ECO:0000305}.
FT   CONFLICT    213    213       A -> G (in Ref. 1; AAB40519).
FT                                {ECO:0000305}.
FT   CONFLICT    398    398       V -> E (in Ref. 1; AAB40519).
FT                                {ECO:0000305}.
FT   CONFLICT    409    412       RDFN -> QDCS (in Ref. 1; AAB40519).
FT                                {ECO:0000305}.
FT   CONFLICT    419    419       K -> E (in Ref. 1; AAB40519).
FT                                {ECO:0000305}.
FT   TURN         41     43       {ECO:0000244|PDB:2PG5}.
FT   HELIX        46     48       {ECO:0000244|PDB:2PG5}.
FT   HELIX        51     53       {ECO:0000244|PDB:2P85}.
FT   HELIX        54     65       {ECO:0000244|PDB:2PG5}.
FT   STRAND       67     73       {ECO:0000244|PDB:2PG5}.
FT   STRAND       76     81       {ECO:0000244|PDB:2PG5}.
FT   HELIX        84     91       {ECO:0000244|PDB:2PG5}.
FT   TURN         92     98       {ECO:0000244|PDB:2PG5}.
FT   HELIX       105    111       {ECO:0000244|PDB:2PG5}.
FT   TURN        116    118       {ECO:0000244|PDB:2PG5}.
FT   HELIX       121    137       {ECO:0000244|PDB:2PG5}.
FT   TURN        138    141       {ECO:0000244|PDB:2PG5}.
FT   HELIX       143    161       {ECO:0000244|PDB:2PG5}.
FT   TURN        162    165       {ECO:0000244|PDB:2PG5}.
FT   HELIX       171    187       {ECO:0000244|PDB:2PG5}.
FT   HELIX       196    212       {ECO:0000244|PDB:2PG5}.
FT   HELIX       215    227       {ECO:0000244|PDB:2PG5}.
FT   STRAND      230    232       {ECO:0000244|PDB:2PG5}.
FT   HELIX       233    256       {ECO:0000244|PDB:2PG5}.
FT   HELIX       267    277       {ECO:0000244|PDB:2PG5}.
FT   TURN        278    280       {ECO:0000244|PDB:2PG5}.
FT   HELIX       288    319       {ECO:0000244|PDB:2PG5}.
FT   HELIX       321    334       {ECO:0000244|PDB:2PG5}.
FT   STRAND      337    339       {ECO:0000244|PDB:2PG5}.
FT   HELIX       343    348       {ECO:0000244|PDB:2PG5}.
FT   HELIX       350    363       {ECO:0000244|PDB:2PG5}.
FT   STRAND      378    380       {ECO:0000244|PDB:2PG5}.
FT   STRAND      383    385       {ECO:0000244|PDB:2PG5}.
FT   STRAND      390    393       {ECO:0000244|PDB:2PG5}.
FT   HELIX       395    399       {ECO:0000244|PDB:2PG5}.
FT   TURN        402    404       {ECO:0000244|PDB:2PG5}.
FT   HELIX       413    416       {ECO:0000244|PDB:2PG5}.
FT   STRAND      419    421       {ECO:0000244|PDB:4EJH}.
FT   HELIX       442    459       {ECO:0000244|PDB:2PG5}.
FT   STRAND      460    466       {ECO:0000244|PDB:2PG5}.
FT   HELIX       468    470       {ECO:0000244|PDB:2PG5}.
FT   STRAND      476    483       {ECO:0000244|PDB:2PG5}.
FT   STRAND      489    493       {ECO:0000244|PDB:2PG5}.
SQ   SEQUENCE   494 AA;  56688 MW;  A39F18AD71C28821 CRC64;
     MLASGLLLVT LLACLTVMVL MSVWRQRKSR GKLPPGPTPL PFIGNYLQLN TEQMYNSLMK
     ISERYGPVFT IHLGPRRVVV LCGHDAVKEA LVDQAEEFSG RGEQATFDWL FKGYGVAFSN
     GERAKQLRRF SIATLRGFGV GKRGIEERIQ EEAGFLIDAL RGTHGANIDP TFFLSRTVSN
     VISSIVFGDR FDYEDKEFLS LLRMMLGSFQ FTATSTGQLY EMFSSVMKHL PGPQQQAFKE
     LQGLEDFIAK KVEHNQRTLD PNSPRDFIDS FLIRMQEEEK NPNTEFYLKN LVMTTLNLFF
     AGTETVSTTL RYGFLLLMKH PEVEAKVHEE IDRVIGKNRQ PKFEDRAKMP YTEAVIHEIQ
     RFGDMLPMGL AHRVNKDTKF RDFFLPKGTE VFPMLGSVLR DPRFFSNPRD FNPQHFLDKK
     GQFKKSDAFV PFSIGKRYCF GEGLARMELF LFFTTIMQNF RFKSPQSPKD IDVSPKHVGF
     ATIPRNYTMS FLPR
//
